Circulating tumor DNA predicts recurrence and splits disease into two subgroups of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity.
Circulating tumor DNA predicts recurrence and splits disease into two subgroups of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity.